AbbVie and Tentarix collaborate on oncology and immunology treatments

Betsy Goodfellow | February 23, 2024 | News story | Research and Development AbbVie, Oncology, collaboration, immunology 

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.

The collaboration is intended to utilise AbbVie’s expertise in oncology and immunology with Tentarix’s proprietary Tentacles platform.

Under the terms of this agreement, Tentarix will receive upfront payment options with a total of $64m from AbbVie for the two programmes.

Jonathon Sedgwick PhD, senior vice president and global head of discover research at AbbVie, commented: “Oncology and immunology are two of our key strategic growth areas where we are pursuing novel technologies that aim to deliver transformative therapies, which address unmet patient needs. This strategic partnership complements our ongoing efforts in developing novel biologics, potentially to expand our oncology and immunology portfolios with conditionally-active multi-specific molecules.”

Don Santel, interim chief executive officer at Tentarix Biotherapeutics, added: “We are excited to join forces with AbbVie to help accelerate cutting-edge, conditionally-active therapeutic programmes towards clinical applications for patients in need. This collaboration adds to our portfolio of internal and external pipeline programmes and is a strong validation of our approach in understanding and targeting complex immune interactions that drive cancers and inflammatory diseases.”

Betsy Goodfellow

Related Content

AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …

BioGen to acquire Human Immunology Biosciences for $1.15bn

BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive …

Sanofi, Formation Bio and OpenAI enter AI collaboration

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with …

Latest content